Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does.

Eli Lilly hasn't split its stock in nearly 30 years, but as shares trade above $1,000, the pharmaceutical company could be considering one. Considering other high-profile stock splits in recent years, count on company-specific catalysts, not the split itself, to drive further gains.

The Motley Fool • 9 hours ago

Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years

The company's GLP-1 therapies are adding indications. Lilly's growing revenue has allowed it to invest heavily in its pipeline.

The Motley Fool • 7 hours ago

Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.

Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.

Market Watch • 15 hours ago

Lilly (LLY) Down 2.7% Since Last Earnings Report: Can It Rebound?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 4, 2026

Great News for Eli Lilly Stock Investors

Eli Lilly's tirzepatide is showing potential across autoimmune diseases. The medicine could earn additional indications and attract broader insurance coverage over time.

The Motley Fool • Sep 3, 2026

Aspen sees Mounjaro Africa sales above $124 million in 2027

Aspen Pharmacare expects African sales ‌of Eli Lilly's blockbuster weight-loss and diabetes drug Mounjaro to exceed 2 billion rand ($124 million) in its current financial year, buoyed by surging demand in South Africa and planned launches in ​Nigeria and Kenya.

Reuters • Sep 3, 2026

Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense

Drugmakers are getting a boost from strong earnings and M&A. But they're also havens in a rocky market.

Barrons • Sep 3, 2026

Eli Lilly Just Announced a Major Acquisition. Here's What It Means.

Lilly has acquired some 26 companies since 2023. Sales of its GLP-1 drug are funding the deals.

The Motley Fool • Sep 2, 2026

Lilly's Record Stock Price Is Hiding an Even Bigger Opportunity

Eli Lilly just delivered one of the biggest quarters in Big Pharma history, yet the stock sits well below its 52-week high. A closer look at the pipeline and valuation reveals why the real opportunity may still be ahead.

24/7 Wall Street • Sep 2, 2026

Lilly's Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity

Eli Lilly and Company TodayLLYEli Lilly and Company$1,171.40 +11.40 (+0.98%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$712.05▼$1,292.65Dividend Yield0.59%P/E Ratio39.28Price Target$1,292.18Add to WatchlistOn Aug. 31, Eli Lilly & Co. NYSE: LLY announced its intention to acquire Merida Biosciences for $2.875 billion.

MarketBeat • Sep 2, 2026